[go: up one dir, main page]

MX2020005640A - Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. - Google Patents

Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.

Info

Publication number
MX2020005640A
MX2020005640A MX2020005640A MX2020005640A MX2020005640A MX 2020005640 A MX2020005640 A MX 2020005640A MX 2020005640 A MX2020005640 A MX 2020005640A MX 2020005640 A MX2020005640 A MX 2020005640A MX 2020005640 A MX2020005640 A MX 2020005640A
Authority
MX
Mexico
Prior art keywords
treatment
breast cancer
antibodies
humanized anti
liv
Prior art date
Application number
MX2020005640A
Other languages
English (en)
Inventor
Ana Kostic
Baiteng Zhao
Dana Kennedy
Elizabeth Corwin
Jonathan Drachman
Peter Haughney
Phillip Garfin
Corinna Palanca-Wessels
ABIDOYE Oyewale O
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2020005640A publication Critical patent/MX2020005640A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para utilizar anticuerpos anti-LIV1, incluidos anticuerpos anti-LIV1 conjugados con fármacos, para inhibir la proliferación de una célula que expresa LIV-1, así como para el tratamiento de una o más enfermedades o trastornos asociados con células que expresan LIV-1 (e.g., un cáncer de mama asociado con LIV-1).
MX2020005640A 2017-12-01 2018-11-30 Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. MX2020005640A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593660P 2017-12-01 2017-12-01
PCT/US2018/063425 WO2019109007A1 (en) 2017-12-01 2018-11-30 Humanized anti-liv1 antibodies for the treatment of breast cancer

Publications (1)

Publication Number Publication Date
MX2020005640A true MX2020005640A (es) 2020-08-20

Family

ID=64746653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005640A MX2020005640A (es) 2017-12-01 2018-11-30 Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.

Country Status (14)

Country Link
US (2) US20200283540A1 (es)
EP (1) EP3717518A1 (es)
JP (2) JP2021505540A (es)
KR (1) KR20200090838A (es)
CN (1) CN111757892A (es)
AU (1) AU2018375182A1 (es)
BR (1) BR112020010937A2 (es)
CA (1) CA3084495A1 (es)
EA (1) EA202091360A1 (es)
IL (1) IL274766A (es)
MA (1) MA50943A (es)
MX (1) MX2020005640A (es)
SG (1) SG11202004751TA (es)
WO (1) WO2019109007A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2648752T1 (sl) 2010-12-06 2017-06-30 Seattle Genetics, Inc. Humanizirana protitelesa proti Liv-1 in njihova uporaba za zdravljenje raka
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
GB201908208D0 (en) * 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent
EP4004046A1 (en) * 2019-07-22 2022-06-01 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
BR112022011268A2 (pt) * 2019-12-09 2022-09-06 Seagen Inc Terapia de combinação com antagonista de liv1-adc e pd1
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2023241621A1 (zh) * 2022-06-16 2023-12-21 山东博安生物技术股份有限公司 抗liv-1抗体及其药物偶联物
KR20250141223A (ko) 2023-02-07 2025-09-26 라노바 메디신즈 리미티드 Liv-1을 표적화하는 항체 및 이의 용도
EP4682168A1 (en) * 2023-03-15 2026-01-21 BioRay Pharmaceutical Co., Ltd. Anti-liv-1 antibody and anti-liv-1 antibody-drug conjugate, and pharmaceutical use thereof
WO2025146137A1 (zh) * 2024-01-05 2025-07-10 海南先声再明医药股份有限公司 抗liv-1抗体药物偶联物及其用途
CN120040587B (zh) * 2025-04-27 2025-08-08 上海宏成药业有限公司 抗liv-1抗体或其抗原结合片段及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
BR122018071808B8 (pt) * 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
EP3498289A1 (en) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
BRPI0710616A2 (pt) * 2006-04-13 2011-08-16 Novartis Vaccines & Diagnostic métodos para tratar, diagnosticar ou detectar cáncer
ES2599172T3 (es) 2007-10-19 2017-01-31 Seattle Genetics, Inc. Agentes de unión a CD19 y usos de éstos
SI2648752T1 (sl) * 2010-12-06 2017-06-30 Seattle Genetics, Inc. Humanizirana protitelesa proti Liv-1 in njihova uporaba za zdravljenje raka
EP2847226A4 (en) * 2012-05-11 2016-05-11 Merrimack Pharmaceuticals Inc DOSAGE AND ADMINISTRATION OF BIS SPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTICROBIAL AGENTS
US9492566B2 (en) * 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US20150343077A1 (en) * 2014-05-13 2015-12-03 Immunogen, Inc. Anti-CD37 Immunoconjugate Dosing Regimens
MA45324A (fr) * 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique

Also Published As

Publication number Publication date
US20200283540A1 (en) 2020-09-10
MA50943A (fr) 2020-10-07
CA3084495A1 (en) 2019-06-06
SG11202004751TA (en) 2020-06-29
IL274766A (en) 2020-07-30
EP3717518A1 (en) 2020-10-07
JP2021505540A (ja) 2021-02-18
AU2018375182A1 (en) 2020-06-11
BR112020010937A2 (pt) 2020-11-17
CN111757892A (zh) 2020-10-09
WO2019109007A1 (en) 2019-06-06
JP2024001187A (ja) 2024-01-09
US20240076402A1 (en) 2024-03-07
EA202091360A1 (ru) 2020-08-24
KR20200090838A (ko) 2020-07-29

Similar Documents

Publication Publication Date Title
MX2020005640A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2020005463A (es) Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12019501959A1 (en) Therapeutic rna
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
EP4268843A3 (en) Improved il-6 antibodies
EP4552698A3 (en) Methods of treating prostate cancer
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
MX2018005348A (es) Composiciones y metodos para transduccion de tumores.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
WO2017035319A8 (en) Methods for treatment of polycystic kidney disease
JOP20200090A1 (ar) عملية لتحضير بنزوثيوفين-2 يل بورونات